



FOR IMMEDIATE RELEASE

June 4, 2004

**BIOLEX ADVANCES DEVELOPMENT OF
A CENTOCOR THERAPEUTIC PROTEIN CANDIDATE**

PITTSBORO, NC, JUNE 4, 2004: Biolex, Inc., a privately held protein therapeutics company, and Centocor, Inc., a wholly owned subsidiary of Johnson & Johnson, have expanded their collaboration to include a limited scale-up of the first of three Centocor proteins expressed using Biolex' proprietary LEX System™. In addition, Centocor has added a fourth protein to its ongoing collaboration with Biolex.

“We are extremely pleased with the progress that has been made in this collaboration to date, as well as with Centocor’s ongoing support in applying our LEX System™ to the expression of a fourth protein,” said Jan Turek, President and CEO of Biolex. “This agreement further validates the ability of the LEX System™ to rapidly express and produce protein therapeutics.”

With the addition of this new protein, Biolex is now evaluating the expression of four of Centocor’s therapeutic proteins using its proprietary LEX System™. At Centocor’s option, Biolex may scale-up and manufacture these proteins following the commercial line creation phase. Financial terms of the collaboration have not been disclosed.

The LEX System™ couples natural characteristics of the small green aquatic plant, *Lemna*, with advanced genetic engineering and protein recovery methods to create a transformational development and production technology with advantages over all other existing cell culture and next generation transgenic expression systems. The LEX System™ has been demonstrated to significantly enable hard-to-make proteins (such as peptides and cytokines) and monoclonal antibodies.

About Biolex: Biolex, Inc. is a private, venture capital-backed biopharmaceutical company. Biolex is developing recombinant human therapeutic proteins that, until now, have been impossible or very expensive to develop in existing expression systems. Biolex’ proprietary LEX System™ has demonstrated speed, regulatory and economic benefits with hard-to-make proteins and monoclonal antibodies. Biolex is developing a pipeline of proprietary products, and is partnering with pharmaceutical and biotechnology companies seeking the protein development and production benefits the LEX System™ offers. Biolex’ corporate partners include Bayer Corporation, Centocor, Inc., Debiopharm S.A., and a major pharmaceutical company. The Company’s headquarters, research laboratories and clinical manufacturing facilities are based in Pittsboro, North Carolina. Visit the Company’s web site at www.biolex.com.

Contact: John Irick, Senior Vice President and Chief Business Officer, Biolex, Inc. 919-542-9901; Michelle Linn, Linnden Communications, 508-869-0138, michlinn@charter.net

###



158 Credle Street
Pittsboro, NC 27312
www.biolex.com

tel 919.542.9901
fax 919.542.9910